- Active not recruitingPHASE3
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
This study looks at a new combination of drugs, cabozantinib and atezolizumab, for men with prostate cancer that has spread and is no longer responding to hormone therapy. It compares this new combination with standard hormone treatments to see if it works better.
For: Metastatic Prostate Cancer · Prostate AdenocarcinomaUnited States · Argentina · Australia - Active not recruitingPHASE2
A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer
This study is testing new immune-based treatments for a type of bladder cancer that has spread. Researchers want to see if combinations of medicines like tobemstomig and tiragolumab are safe and work better than atezolizumab for people who can't have standard chemotherapy.
For: Urothelial CancerUnited States · Australia · Brazil - Not yet recruitingPHASE1, PHASE2
DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers
This study tests new medicines, obrixtamig and ZL-1310, for advanced lung and other neuroendocrine cancers. It aims to find a safe dose and see how they work, especially when combined with another drug to help your immune system fight cancer.
For: Small Cell Lung Cancer · Large Cell Neuroendocrine Lung Carcinoma · Extrapulmonary Neuroendocrine Carcinoma of Small Cell HistologyUnited States · Australia · Belgium - Active not recruitingPHASE2
A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung
This study is looking at a new treatment called Atezolizumab for a type of lung cancer called large-cell neuroendocrine carcinoma. It combines Atezolizumab with standard chemotherapy to see if it's safe and effective for people whose cancer has spread or can't be cured with other treatments.
For: Large Cell Neuroendocrine Carcinoma of the LungGermany - Active not recruiting
An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery
This study looks at how well different treatments work for adults with liver cancer that can't be removed by surgery. Researchers are collecting health information from medical records to find the best next steps for people who have already had a specific type of first-line therapy.
For: Unresectable Hepatocellular CarcinomaUnited States · Argentina · Brazil - Active not recruitingPHASE1
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
This study is looking into new ways to treat advanced cancers that have a specific genetic change called KRAS p.G12C. It's testing a drug called sotorasib, either by itself or with other treatments, to see how safe and effective they are for adults.
For: Advanced Solid Tumors · Kirsten Rat Sarcoma (KRAS) pG12C MutationUnited States · Australia · Austria - RecruitingPHASE3
The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma
This study compares two treatments for a type of liver cancer called hepatocellular carcinoma (HCC) in its intermediate stage. It looks at a combination of two drugs, atezolizumab and bevacizumab, against a standard treatment called TACE (Transarterial Chemoembolization), to see which works best and is safest.
For: Hepatocellular CarcinomaAustria · France · Germany - Active not recruitingPHASE3
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)
This study is looking at new ways to treat advanced liver cancer that can't be removed by surgery. It combines existing medications with a new one to see if this mix works better and is safe. The aim is to find improved first-line treatments for this type of cancer.
For: Hepatocellular CarcinomaUnited States · Belgium · Brazil - RecruitingPHASE3
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
This study is for adults with a certain type of lung cancer (Stage II-IIIB non-small cell lung cancer) that has a specific genetic change (HER2 mutation) and has been fully removed by surgery. It compares a new daily tablet called zongertinib with standard treatments to see if it can stop the cancer from coming back.
For: Non-small Cell Lung CancerUnited States · Argentina · Australia - RecruitingPHASE3
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
This study compares a new combination medicine, BMS-986489 (BMS-986012 and Nivolumab), with a standard treatment (Atezolizumab), both given with chemotherapy. It's for people with a type of lung cancer called extensive-stage small cell lung cancer who are starting their first treatment.
For: Extensive-Stage Small Cell Lung CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
This study is looking at a new treatment for liver cancer to stop it coming back after surgery or other procedures. It compares two drugs, atezolizumab and bevacizumab, with regular check-ups to see which is better at preventing the cancer from returning.
For: Carcinoma, HepatocellularUnited States · Australia · Austria - Active not recruitingPHASE2
NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing
This study looks at combining chemotherapy with two new drugs, tiragolumab and atezolizumab, before and after surgery for certain lung cancers. It aims to see if this combination is safe and effective for patients with non-small cell lung cancer.
For: Non-small Cell Lung CancerGermany - RecruitingPHASE3
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
This study is testing a new drug, Pumitamig, with chemotherapy for people with advanced small-cell lung cancer that hasn't been treated before. It aims to see if this new combination works better and is safe compared to a standard treatment.
For: Extensive-stage Small-cell Lung CancerUnited States · Australia · China - Active not recruitingPHASE1, PHASE2
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
This study is testing a new combination treatment for a type of lung cancer called Extensive Stage Small Cell Lung Cancer (ES-SCLC). It aims to find a safe dose and see if this new combination works better than current treatments for people newly diagnosed with this aggressive cancer.
For: Extensive Stage Small Cell Lung CancerUnited States · Austria · Canada - Active not recruitingPHASE3
Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)
This study looked at new ways to treat a type of lung cancer called extensive-stage small cell lung cancer (ES-SCLC). It compared a combination of medicines with standard chemotherapy to see if it could help people live longer. The study was changed partway through, so the focus shifted.
For: Small Cell Lung CarcinomaUnited States · Argentina · Australia - Active not recruitingPHASE1
A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers
This study looks at a new drug, inavolisib, alone or with another drug, atezolizumab, for cancers with a specific change (PIK3CA mutation). It aims to see if they are safe and work well, especially for certain head and neck cancers.
For: PIK3CA-Mutated CancersUnited States · Canada · South Korea - Active not recruitingPHASE3
A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
This study looks at new drug combinations for advanced liver cancer that has already been treated. It compares atezolizumab with lenvatinib or sorafenib against lenvatinib or sorafenib alone, to see if the combinations work better and are safe.
For: Unresectable Hepatocellular CarcinomaAustria · Belgium · Brazil - RecruitingPHASE2, PHASE3
A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
This study is looking into new treatments for advanced liver cancer (hepatocellular carcinoma). It compares new drug combinations, livmoniplimab with budigalimab, against existing treatments to find the best dose and see how well they work and what side effects they might have.
For: Hepatocellular CarcinomaUnited States · France · Italy - Active not recruitingPHASE3
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
This study compares a new treatment, Atezolizumab, to standard care for patients with early-stage lung cancer after surgery and chemotherapy. It aims to see if Atezolizumab can prevent the cancer from returning and help people live longer.
For: Non-Small Cell Lung CancerUnited States · Australia · Belgium - Active not recruitingPHASE1
Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCC
This study is looking into a new treatment for advanced liver cancer (hepatocellular carcinoma) that can't be removed by surgery. It combines a new drug, NP137, with two existing drugs, Atezolizumab and Bevacizumab, to see if it's safe and helps people live longer and respond better to treatment.
For: Hepatocellular CarcinomaFrance - Active not recruitingPHASE1, PHASE2
An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
This study looks at new drug combinations for adults with a type of blood cancer called Non-Hodgkin's Lymphoma that has come back or not responded to previous treatments. It aims to find the safest dose and see how well these new treatments work.
For: Non-Hodgkins LymphomaBelgium · Denmark · Israel - Active not recruitingPHASE2, PHASE3
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
This study looks at new drug combinations for advanced non-small cell lung cancer. It aims to find out how safe and effective these treatments are for people whose cancer has specific genetic changes, using blood tests to identify these changes.
For: Non-Small Cell Lung CancerUnited States · Argentina · Australia - RecruitingPHASE1
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
This study looks at new treatments for bowel cancer that has spread. We want to see if these targeted medicines or immunotherapy are safe and work well for people whose cancer has specific genetic features, which we call biomarkers.
For: Metastatic Colorectal CancerUnited States · Australia · Canada - Active not recruitingPHASE3
Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy
This study looks at a new treatment for advanced lung cancer in people aged 70-89. It combines standard chemotherapy (Carboplatin, Paclitaxel) with an immunotherapy drug called Atezolizumab, to see if it's effective and well-tolerated in this age group.
For: Non Small Cell Lung Cancer MetastaticFrance - RecruitingPHASE1, PHASE2
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
This study looks at different treatment combinations for advanced breast cancer, including those that have spread or are hard to remove. Doctors want to see how well these new drug combinations work and if they are safe for patients.
For: Metastatic Breast CancerUnited States · Australia · France - RecruitingPHASE2
Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity
This study looks at a medicine called atezolizumab for different cancers. We want to see if a special test of your cancer cells can predict if the medicine will work well for you. This helps us learn more about tailoring treatments.
For: Breast Cancer · Lung Cancer · Gastrointestinal CancerCanada - RecruitingPHASE2
Neoadjuvant Immune Checkpoint Inhibitor Treatment in Urothelial Cancer
This study looks at a drug called atezolizumab for certain urinary system cancers before surgery. It aims to see if the drug can shrink tumours, making surgery more effective. The drug works by helping your body's immune system fight the cancer.
For: Urogenital CancerUnited Kingdom - Active not recruitingPHASE3
Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer
This study compares two treatments, XL092 (plus atezolizumab) and regorafenib, for advanced bowel cancer that has spread. It's for people whose cancer hasn't responded well to previous common treatments. We want to see which treatment works better to control the cancer.
For: Colorectal CancerUnited States · Australia · Belgium - Active not recruitingPHASE2
Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma
This study is testing a new medicine, Atezolizumab, for children and young people aged 2 to 17 with certain types of rare cancers: clear cell sarcoma or chondrosarcoma. It aims to see how well the medicine helps the body's immune system fight the cancer.
For: Central Chondrosarcoma, Grade 2 · Central Chondrosarcoma, Grade 3 · Dedifferentiated ChondrosarcomaUnited States · Canada - Active not recruitingPHASE1
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
This study is testing a new medicine, GDC-6036, for people with advanced cancers that have a specific genetic change called KRAS G12C. It will look at how safe the medicine is and if it helps shrink tumors, sometimes combined with other treatments.
For: Non-Small Cell Lung Cancer · Colorectal Cancer · Advanced Solid TumorsUnited States · Australia · Belgium - Active not recruitingPHASE2
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
This study is for people with advanced solid cancers that haven't responded to other treatments. It uses a "precision medicine" approach, matching treatments to the specific genetic changes found in each person's tumour, aiming for more effective and personalised care.
For: Solid TumorsUnited States · Australia · Belgium - Active not recruitingPHASE2
Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy
This study looks at new ways to treat advanced non-small cell lung cancer that has grown despite previous treatments. It compares two different drug combinations, one with an extra anti-cancer medicine called atezolizumab, to see if they can help patients live longer without their cancer getting worse.
For: Non Small Cell Lung CancerFrance - RecruitingPHASE3
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy
This study looks at a new medicine called obrixtamig for advanced small cell lung cancer. It compares obrixtamig plus standard treatment against standard treatment alone to see if it helps people live longer. It also tests a device to measure a cancer marker.
For: Small Cell Lung Cancer (SCLC) · Extensive-stage Small Cell Lung Cancer (ES-SCLC)United States · Argentina · Australia - RecruitingPHASE2
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
This study looks at new treatments for pancreatic cancer after surgery. It compares a new combination of drugs (Autogene Cevumeran, Atezolizumab, and mFOLFIRINOX) with a standard treatment (mFOLFIRINOX alone) to see which works best and is safest for patients with no remaining cancer after their operation.
For: Adenocarcinoma, Pancreatic DuctalUnited States · Belgium · Canada - Active not recruitingPHASE2
Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness
This study compares a new drug, atezolizumab, plus standard chemotherapy (FLOT) against FLOT alone for stomach or food pipe cancer. It focuses on patients whose cancer shows certain immune markers, aiming to see if the new combination is safer and more effective before and after surgery.
For: Gastric Cancer · Gastroesophageal Junction AdenocarcinomaGermany · Switzerland - Active not recruitingPHASE3
Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy
This study looks at new drug combinations for advanced liver cancer that hasn't been treated before. It compares cabozantinib with atezolizumab against a standard treatment, sorafenib, to see which works better and is safer.
For: Hepatocellular CarcinomaUnited States · Argentina · Australia - RecruitingPHASE3
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
This study aims to see if a special ultrasound device, Exablate, can help standard cancer medicines work better for people with lung cancer that has spread to the brain. Researchers will compare this new approach to standard care alone.
For: Brain Tumor · Non Small Cell Lung CancerUnited States · Canada · South Korea - RecruitingPHASE3
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
This study offers continued treatment to cancer patients already in certain Genentech/Roche studies. It's for those still benefiting from their current treatment and who can't get it elsewhere. The aim is to bridge care for these patients.
For: CancerBelgium · Canada · China - Active not recruitingPHASE1, PHASE2
A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab
This study is testing new combinations of drugs for advanced stomach and bowel cancers, including anal and pancreatic cancers. We want to see if these treatments are safe and if they help shrink tumors or stop them from growing. It involves several groups, some trying new drug combinations.
For: Anal Cancer Metastatic · Squamous Cell Carcinoma of the Anus Stage Unspecified · Pancreatic Cancer MetastaticGermany - RecruitingPHASE2, PHASE3
DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol
The DETERMINE trial is testing if existing cancer medicines can help people with rare cancers or common cancers with rare genetic changes. It includes adults, teenagers, and children. The goal is to find new ways to treat cancer and make these treatments available through the NHS.
For: Haematological Malignancy · Solid TumourUnited Kingdom - Active not recruitingPHASE3
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
This study allows some cancer patients who are already benefiting from certain treatments in another study to continue receiving that treatment. It’s for those who wouldn't be able to get the treatment otherwise, helping them keep accessing therapies that are working for them.
For: CancerUnited States · Australia · Belgium - Active not recruitingPHASE4
Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma
This study looks at new ways to treat advanced lung cancer that has spread. It compares two different drug combinations to see which works better for a specific type of lung cancer that doesn't have certain features.
For: Non-Small Cell Lung Cancer MetastaticGermany - Active not recruitingPHASE3
Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients
This study looks at a new combination treatment for a type of early bladder cancer. It compares giving a standard treatment called BCG alongside a new drug called atezolizumab to just giving BCG alone. The aim is to see if the combination works better at preventing the cancer from coming back.
For: Bladder CancerBelgium · France · Spain - RecruitingPHASE3
Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated
This study compares a new drug called tepotinib with standard treatments for advanced lung cancer. It's for people whose cancer has a specific change (MET Exon 14 mutation) and has already been treated. The aim is to see if tepotinib works better to stop the cancer from growing.
For: Advanced Non Small Cell Lung Cancer · MET Exon 14 MutationFrance - RecruitingPHASE2, PHASE3
DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
This study is testing a cancer drug called atezolizumab in people with certain cancers that have specific genetic changes. Atezolizumab is already used for some cancers, and this study wants to see if it can help other types of cancer that share these same genetic features.
For: Malignancy · Malignant Neoplasm · Lymphoproliferative DisordersUnited Kingdom - Recruiting
A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice
This study looks at how well a medicine called Atezolizumab works and how happy people are with it when used for lung cancer or a type of liver cancer in normal NHS care. It also checks for side effects.
For: Lung Cancer, Hepatocellular CarcinomaAustria · Belgium · Bulgaria - Active not recruiting
A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice
This study looks at how a cancer drug called atezolizumab works in real patients. Researchers want to see its effects and safety under normal hospital care, for different types of cancer it's approved for.
For: Urothelial Carcinoma · Non-Small Cell Lung Cancer · Small Cell Lung CancerArgentina · Austria · Belgium - Active not recruitingPHASE2
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
This study is looking at new treatments for a specific type of ovarian cancer that has come back or won't go away. We want to see if these treatments are safe and effective for patients whose cancer has certain genetic features.
For: Ovarian CancerUnited States · Australia · Canada - Active not recruitingPHASE3
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
This study looked at new treatments for HER2-positive breast cancer that had already been treated but still showed signs of cancer after surgery. Researchers wanted to see if adding certain drugs could prevent the cancer from coming back.
For: Breast CancerUnited States · Australia · Austria - RecruitingPHASE3
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
This study is testing new combinations of medicines for advanced liver cancer (hepatocellular carcinoma) that can't be cured with surgery. It compares different drug blends to a common treatment to see which works best and is safest.
For: Hepatocellular CarcinomaUnited States · Australia · Brazil